浅谈痛风及高尿酸血症治疗热点问题
朱小霞 . 浅谈痛风及高尿酸血症治疗热点问题[J]. 内科理论与实践, 2022 , 17(03) : 198 -201 . DOI: 10.16138/j.1673-6087.2022.03.005
| [1] | Zhang M, Zhu XX, Wu J, et al. Prevalence of hyperuricemia among Chinese adults: findings from two nationally representative cross-sectional surveys in 2015-16 and 2018-19[J]. Front Immunol, 2022, 12: 791983. |
| [2] | Yu KH, Chen DY, Chen JH, et al. Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan[J]. Int J Rheum Dis, 2018. 21(4): 772-787. |
| [3] | White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout[J]. N Engl J Med, 2018, 378(13): 1200-1210. |
| [4] | Zhang M, Solomon DH, Desai RJ, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol[J]. Circulation, 2018, 138(11): 1116-1126. |
| [5] | Chen CH, Chen CB, Chang CJ, et al. Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians[J]. Clin Pharmacol Ther, 2019, 106(2): 391-401. |
| [6] | Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout(FAST)[J]. Lancet, 2020, 396(10264): 1745-1757. |
| [7] | Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med, 2019, 381(26): 2497-2505. |
| [8] | Shah B, Toprover M, Crittenden DB, et al. Colchicine use and incident coronary artery disease in male patients with gout[J]. Can J Cardiol, 2020, 36(11): 1722-1728. |
| [9] | Yamanaka H, Tamaki S, Ide Y, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study[J]. Ann Rheum Dis, 2018, 77(2): 270-276. |
| [10] | Xue X, Liu Z, Li X, et al. The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study[J]. Rheumatology (Oxford), 2021, 60(6): 2661-2671. |
/
| 〈 |
|
〉 |
